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ABSTRACT
Imidazopyrazinones (IPYs) are a new class of com-
pounds that target bacterial topoisomerases as a ba-
sis for their antibacterial activity. We have charac-
terized the mechanism of these compounds through
structural/mechanistic studies showing they bind
and stabilize a cleavage complex between DNA gy-
rase and DNA (‘poisoning’) in an analogous fash-
ion to fluoroquinolones, but without the requirement
for the water–metal–ion bridge. Biochemical experi-
ments and structural studies of cleavage complexes
of IPYs compared with an uncleaved gyrase–DNA
complex, reveal conformational transitions coupled
to DNA cleavage at the DNA gate. These involve
movement at the GyrA interface and tilting of the
TOPRIM domains toward the scissile phosphate cou-
pled to capture of the catalytic metal ion. Our exper-
iments show that these structural transitions are in-
volved generally in poisoning of gyrase by therapeu-
tic compounds and resemble those undergone by the
enzyme during its adenosine triphosphate-coupled
strand-passage cycle. In addition to resistance mu-
tations affecting residues that directly interact with
the compounds, we characterized a mutant (D82N)
that inhibits formation of the cleavage complex by
the unpoisoned enzyme. The D82N mutant appears
to act by stabilizing the binary conformation of DNA
gyrase with uncleaved DNA without direct interac-
tion with the compounds. This provides general in-
sight into the resistance mechanisms to antibiotics
targeting bacterial type II topoisomerases.
INTRODUCTION
Antibiotics are a cornerstone of modern medicine, under-
pinning modern clinical and ambulatory care. The ability
to prevent and treat infections has led to a huge drop in
mortality and morbidity, and indirectly allowed the devel-
opment of sophisticated surgical procedures. Few discov-
eries can claim to have had such an all-encompassing and
far-reaching effect on human well being. Unfortunately the
levels of antimicrobial resistance (AMR) worldwide are in-
creasing (1,2) while recent decades have seen a paucity of
new antibacterial compounds reaching the clinic (3) or ap-
proved for use (4). On this, see also the material published
by the review on AMR commission chaired by Jim O’Neil,
https://amr-review.org/Publications.html. The current per-
ceived low return on investment in antibacterials does not
encourage significant investment by industry.Moreover, the
discovery and optimization of new antibacterials is intrin-
sically challenging and clinical trials face challenges as well
(5).
Altogether, these issues create a potential ‘perfect storm’
wherein bacterial infections are becoming untreatable with
traditional antibiotics and only limited new options are be-
coming available (6). Among the numerous counter attacks
to fight AMR, the New Drugs For Bad Bugs (ND4BB)
program, funded by the European Union’s Innovative
Medicine Initiative (IMI), includes multiple collaborative
projects, involving both pharmaceutical industries and aca-
demic partners, to accelerate the discovery and develop-
ment of new treatments for resistance to bacterial infec-
tions (7,8).WithinND4BB, the ENABLE consortium tack-
*To whom correspondence should be addressed. Tel: +44 1603 450 771; Fax: +44 1603 450 018; Email: tony.maxwell@jic.ac.uk
Present address: Benjamin Bax, Biological Chemistry (York Structural Biology Laboratory), Department of Biology, University of York, Heslington, York YO10
5DD, UK.
C© The Author(s) 2018. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloaded from https://academic.oup.com/nar/article-abstract/46/8/4114/4925761
by Cardiff University user
on 04 May 2018
Nucleic Acids Research, 2018, Vol. 46, No. 8 4115
les optimization and pre-clinical development of new com-
pounds targeting Gram-negative pathogens by pooling the
expertise of multiple partners to progress early stage drug
discovery projects to key milestones.
DNA topoisomerases are enzymes responsible for the
control of DNA topology in all cells and are classified into
two types, I and II, dependent on whether their reactions
proceed via single- or double-stranded DNA breaks (9,10).
The bacterial type II topoisomerases, topoisomerase IV and
DNA gyrase, are made up of two subunits forming hetero-
tetrameric complexes, which establish a transient double-
stranded DNA break and facilitate the passage of another
DNA segment through the break. DNA gyrase, which con-
sists of two subunits, GyrA and GyrB, forming an A2B2
complex in the active enzyme, wraps a positive turn ofDNA
around itself before the strand-passage event, thereby intro-
ducing negative supercoils. Bacterial type II topoisomerases
are one of only a few clinically-validated targets for antibi-
otics (11). Type II topoisomerases are essential for tran-
scription and genome segregation in bacterial cells and are
the target of a successful family of antibiotics: the fluoro-
quinolones (FQs) (11,12). The FQs intercalate at the sites
of DNA cleavage (the DNA gate), one molecule at each
of the two cleavage sites, separated by four bases. This in-
tercalation stabilizes a cleaved DNA complex (dubbed the
‘cleavage complex’) thereby converting the topoisomerase
from an essential enzyme into aDNA-damaging agent. FQs
and similar agents are therefore called topoisomerase ‘poi-
sons’. The huge clinical success of these compounds has
been undermined by the emergence of resistance, notably
by mutations within the target itself (13). FQs interact, via
a water–metal–ion bridge (14–16), with two residues on the
GyrA subunit of DNA gyrase that are oftenmutated in FQ-
resistant strains of bacteria found in the clinic (14,17–18).
Recently, a variety of compounds targeting bacterial type
II topoisomerases have been reported, including two classes
that have completed phase II trials (19–21). Bacterial type
II topoisomerases can be targeted in various ways through
several binding pockets. However, poisoning remains by far
the most clinically successful way to target type II topoiso-
merases.
As part of a collaboration between Sanofi and GSK
within the ENABLE consortium, the imidazopyrazinones
(IPYs), a series of bactericidal compounds initially discov-
ered by Rhoˆne-Poulenc in an SOS activation assay, have
been the subject of a medicinal chemistry effort for their
pre-clinical optimization (Jeannot et al. In revision in JMed
Chem). To support this effort, structural and mechanistic
studies were performed. The most potent examples of this
IPY series were the result of a structural hybridization be-
tween the initial, Gram-positive-only hits and the quinazo-
linedione series of topoisomerase inhibitors (22). In quina-
zolinediones, the carboxylic acid group of FQs is replaced
with an amine, and nowater–metal–ion bridge is involved in
compound binding to DNA gyrase (23). During the micro-
biological and enzymatic profiling of the IPYs, partial cross
resistance with the FQs was detected leading to the termi-
nation of the optimization effort (Jeannot et al. In revision
in J Med Chem). We have now solved the crystal structure
of selected IPYs bound toDNA gyrase andDNA and show
that these IPYs bind the FQ pocket in a fashion similar to
the FQs, despite the lack of the highly characteristic 4-oxo
and carboxylic acid moieties of FQs. IPYs establish con-
tact with a FQ-resistance-associated residue, thus explain-
ing the observed cross resistance. Through comparison with
a compound-free ‘unpoisoned’ binary gyrase–DNA com-
plex and biochemical experiments, we further show that
conformational changes associated with IPY-induced poi-
soning are highly similar to those observed with FQs and
fit into a general ‘intercalative-poisoning’ scheme. This pro-
vides general insights into this major targeting avenue for
antibiotics and the mechanism of target-based resistance to
topoisomerase inhibitors. We discuss the role of the metal
ions in the poisoned complex, potential strategies for the
development of new type II topoisomerase poisons and the
basis for resistance.
MATERIALS AND METHODS
Compound synthesis
Synthetic details for the IPYs are described elsewhere (Jean-
not et al. In revision in J Med Chem), except for compound
b1, whose synthesis and characterization is described in the
‘Supplementary Data’ section.
Supercoiling assays
Supercoiling reactions were carried out as described pre-
viously (24) with minor adjustments. A total of 500 ng of
relaxed pBR322 plasmid was used as a substrate for each
30 l reaction. The amount of DNA gyrase (A2B2) added
was normalized by testing various dilutions of the stock
(A2B2 containing 0.5 mg/ml of each subunit) without com-
pound. The amount sufficient to supercoil 50% of the sub-
strate was then used for the testing of compounds. See Sup-
plementary Figure S1 for details. This ensured a limiting
amount of enzyme for every mutant tested. The individ-
ual gyrase subunits were either prepared in the lab as de-
scribed previously (25) or purchased from Inspiralis. The
IC50 (compound concentration giving only 50% of the su-
percoiled substrate obtained with the uninhibited enzyme)
was determined by plotting the quantified (using ImageJ)
proportion of supercoiled DNA to the total of the lane
against the compound concentration and fitting it to a four-
parameter binding curve (y = min + ((max − min)/(1 +
(x/IC50)∧HillSlope)) with Scipy (26). The measured value
was the best fit for the IC50 parameter. Comparing ourmea-
surement with ciprofloxacin to published results showed
overall consistency and validated our methodology (for in-
stance compare our ciprofloxacin data with those reported
in (27)).
Cleavage assays
Reactions were carried out as described previously (24) with
minor adjustments. A total of 500 ng of relaxed pBR322
plasmid was used as a substrate for each 30 l reaction.
Cleavage complexes were trapped by addition of 7.5 l of
1% (w/v) sodium dodecyl sulphate (SDS). Dimethylsulfox-
ide (DMSO) was absent (Ca2+ re-sealing), or at a concen-
tration of 0.33% (v/v) (ciprofloxacin or t1 resealing) or
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1.66% (v/v) (all other cleavage experiments). When ana-
lyzing cleavage, electrophoresis was performed in the pres-
ence 0.5 g/ml ethidium bromide. In these conditions, in-
tact DNA molecules migrate as a single band (topoisomers
are not resolved). For the ethylenediaminetetraacetic acid
(EDTA) re-sealing experiment, 1 l of a 250 mM stock of
EDTA pH 8.0 was added prior to SDS trapping as above
(after the indicated time). The CC50 was determined exactly
as the IC50 and is defined as the concentration of compound
producing 50% of the maximum cleavage obtained in the
same assay.
Crystallization and data collection
Crystals of DNA–cleavage complexes of two of the IPYs,
t1 and t3, with Staphylococcus aureus DNA gyrase fusion
truncate (GyrB27-A56(GKdel)) were obtained as described
(28). A crystal of t1 gave a 3.06 A˚ dataset in a P21 cell
with two complexes in the asymmetric unit, while a crys-
tal of t3 gave a 3.11 A˚ dataset in a P61 cell with one com-
plex in the asymmetric unit (Supplementary Table S1). We
also obtained a 2.60 A˚ structure of a binary complex of
DNA and with the same S. aureus DNA gyrase core con-
struct in a P21 cell with two complexes in the asymmetric
unit. The sequences of the 20 bp DNA duplexes used to ob-
tain the structures are shown in Supplementary Table S2.
The DNA used in the binary complex (20-447T), has previ-
ously been used in solving two crystal structures of cleavage
complexes with QPT-1 (28). The DNA used in the two IPY
complexes, 20-448T-U, contained an A-U base-pair (Sup-
plementary Table S2) where the DNA is bent by the inser-
tion of Ile 175 (from S. aureus GyrA).
Structure determination and refinement
The structures were determined from previous crystal struc-
tures of S. aureus DNA gyrase (19,21,29–30). Structures
were refined with cycles of rebuilding in Coot (31) and
refinement in Refmac (32), Phenix (33) and BUSTER
(BUSTER version 2.11.5; Global Phasing Ltd: Cambridge,
UK) to give models with good geometry (Supplementary
Table S1). Refinement dictionaries for the two IPYs, t1 and
t3, were generated with AceDRG (34). In the 2.60 A˚ bi-
nary structure the DNA was intact, whereas in the two IPY
structures the DNA had been cleaved and there was a co-
valent phosphotyrosine bond between Tyr123 from GyrA
and the cleaved DNA. The electron density for the four t1
IPYs in the cleaved DNA in the 3.06 A˚ structure and the
two t3 IPYs in the 3.11 A˚ structure is shown in Supplemen-
tary Figure S2. The four t1 IPYs all had reasonable density
and were modeled in the same orientation, with the pen-
dant aminopyrrolidine modeled in different orientations in
the four t1 IPYs (SupplementaryFigure S2). In the 3.11 A˚ t3
complex therewas only one complex in the asymmetric unit.
The electron density for one of the t3 IPYs clearly showed
it bound in the same orientation as the four t1 IPYs, how-
ever, the second t3 IPY had some density for its pyridine
ring which suggested an alternative binding mode (Supple-
mentary Figure S2H). In the final structure for the 3.11 A˚ t3
complex, the compound at the second binding site has been
modeled in two binding modes: the ‘standard’ IPY binding
mode observed at the other five binding sites, and an ‘alter-
native’ binding mode. The electron density near this second
t3 IPY suggested that the DNA was partially cleaved and
partially intact at this site (Supplementary Figure S2I). It
may be that the two binding modes for the t3 IPY at this
second site are related to cleaved and re-ligated structures
of the DNA. Some regions of the TOPRIM domains also
had weak electron density in the IPY structures; most no-
tably residues 438–445 of GyrB, a region close to the dimer
interface.
RESULTS
Imidazopyrazinones (IPYs) stabilize DNA cleavage com-
plexes
The IPY compounds have been shown to target bacterial
type II DNA topoisomerases and show variable levels of
activity against a panel of Gram-negative and/or Gram-
positive bacteria (Jeannot et al. In revision in JMed Chem).
Figure 1 shows structures of three tricyclic IPYs (t1, t2 and
t3) as well as two bicyclic IPYs (b1 and b2) and the FQs
ciprofloxacin andmoxifloxacin. ADNA-cleavage assay per-
formed with purified Escherichia coli DNA gyrase shows
that the IPY t1 induces levels of double-stranded cleavage
comparable to those obtained with ciprofloxacin (Figure 1).
IPYs bind at the quinolone pocket, in the same orientation as
FQs, but without formation of a water–metal–ion bridge
To gain insight into the poisoning mechanism of the IPYs,
we solved crystal structures (Supplementary Table S1) of
DNA–cleavage complexes formed between the S. aureus
GyrB27-A56 (GKdel) fusion truncate (19,2829) and a 200
bpDNA duplex (Supplementary Table S2) and compounds
t1 (Figures 1 and 2) and t3 (Figure 1; Supplementary Fig-
ures S2 and 5). The 20 bp DNA duplex used in these crys-
tal structures was very similar to that previously used in
solving a 2.95 A˚ crystal structure with the FQ moxifloxacin
(Supplementary Table S2 (29)). Although our program was
aimed at developing new gyrase-targeted antibiotics active
against Gram-negative pathogens (e.g. E. coli), crystallog-
raphy of the E. coli gyrase–drug–DNA complexes is not
straightforward and we therefore used the S. aureus DNA
gyrase crystallography platform (28).
The structure reveals a high degree of similarity between
the binding mode of t1 and moxifloxacin involving hemi-
intercalation of the compound at each DNA cleavage site
(Figure 2C–E).Moxifloxacin (and other FQs) interacts with
the protein via a water–metal–ion bridge (15–16,2329) as
shown in Figure 2E. The IPYs, such as t1, lack the metal-
coordinating keto-acid groups of FQs and therefore can-
not form a water–metal–ion bridge. Instead, t1 contacts
the protein through a direct hydrogen bond with SaS84 on
GyrA (equivalent toEcS83––the initial in italics denotes the
species numbering for residues, Ec: E. coli, Sa: S. aureus),
see Figure 2C and D.
The arginine positioned next to the catalytic tyrosine
(R122) contacts the keto group of t1/t3 (Figure 2C and
D) in four of the six binding sites observed (four in the t1
complex and two in the t3 complex asymmetric units; Sup-
plementary Figure S2). This arginine is conserved across
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Figure 1. The imidopyrazinones (IPYs) stabilize gyrase–DNA cleavage
complexes. The compounds used in this study are shown; t1, t2 and t3 are
tricyclic IPYs; b1 and b2 are bicyclic IPYs. t1 efficiently stabilizes double-
strand cleavage complexes with Escherichia coli DNA gyrase and DNA
(top) as evidenced by the induction of linear plasmidDNA in a cleavage as-
say (‘Materials and Methods’ section). Cleavage induced by ciprofloxacin
(cipro) in the same assay is shown below. The migration positions of the
different forms of the plasmid,Nicked, Linear and Intact are labeled on the
left side. The enzyme concentration is identical for the two assays (around
250 ng of A2B2 tetramer for a 30 l reaction). Compound concentrations
are indicated in M at the top of the lane. Moxifloxacin (moxi) is shown
for reference as we use it for our structural discussion.
type IIA topoisomerases and we found it to be essential
for cleavage by the S. aureus fusion truncate (Supplemen-
tary Figure S3), but in the S. aureus gyrase crystal struc-
tures its position is quite variable (29). The distal nitro-
gen of the aminopyrrolidine group in t1 has been modeled
contacting the main-chain carbonyl of arginine 458 (Figure
2D) in some, but not all, subunits (Supplementary Figure
S2). Substitution of this aminopyrrolidine group was part
of the medicinal chemistry effort aimed at reducing cross-
resistance with the FQs through improvement of the con-
tact within the TOPRIM domain (e.g. compound t3 where
the aminopyrrolidine is replaced with a pyridine) although
no breakthroughs were achieved (Jeannot et al. In revision
in J med Chem).
The IPYs poison DNA gyrase in vitro with partial FQ cross-
resistance
The activity of tricyclic and bicyclic IPYs (Figure 1) was
tested in a supercoiling inhibition assay (Table 1) on
wild-type (wt) E. coli DNA gyrase and GyrA mutants
EcS83L (SaS84), EcD87A (SaE88) and EcD82N (SaD83).
These residues are located in the ‘Quinolone-Resistance-
Determining-Region’, frequently found mutated in resis-
tant clinical isolates (18,35–38). Based on the structures
solved of FQs bound to DNA gyrase and topo IV, it has
been established that both residues EcS83 and EcD87 are
involved in a water–metal–ion bridge that is important for
the stabilization of the ternary complex, explaining the re-
sistance to FQs observed when these residues are mutated
(15–16,23,29,39).
We found that the most active tricyclic IPY on TolC
E. coli (compound t1, Jeannot et al. In revision in J Med
Chem) efficiently inhibited the negative supercoiling activ-
ity of E. coli DNA gyrase (IC50 = 0.5 M, Figure 3 and
Table 1). The S83L mutant enzyme showed resistance with
an IC50 of 3.7 M (around a 7-fold increase); in the same
assay, ciprofloxacin displayed an ∼20-fold increase in IC50
with the EcS83L mutant compared to the wt. The EcD87A
mutant enzyme did not show any resistance to the IPY com-
pounds (IC50 of 0.49 M, Table 1 and Figure 3). These re-
sults are consistent with the observed binding mode of t1 in
S. aureus DNA gyrase (Figure 2), in which t1 makes a di-
rect interaction with SaS84 (EcS83) while no direct contact
is observed between the IPY and SaE88 (EcD87).
In the supercoiling inhibition assay the EcD82N mutant
showed cross-resistance to t1 (IC50 of 9.4 M). The EcD82
(SaD83) residue does not appear to be involved in binding
to the IPYs or FQs at the cleavage site (Figure 2C–E) and
likely has another role in poisoning (see below). Other tri-
cyclic IPY compounds tested (t2 and t3, Figure 1) similarly
encountered partial resistance with theEcS83Lmutant, low
to no resistance with the EcD87A mutant, and high resis-
tance with EcD82N (a precise value could not be deter-
mined as we could not fit the data, but is likely to be between
4 and 20 M) (Table 1). These results suggest a common
binding mode across the tricyclic series. The stabilization of
gyrase-induced double-stranded DNA cleavage stimulated
by t1 (Figure 1) was also observed with other IPYs (Table
2). The CC50 for t1 was 0.75–0.98 M (ciprofloxacin gave
a CC50 of ∼0.2–0.42 M in the same assay; Table 2 and
Supplementary Figure S4). We have also performed CC50
measurements with ciprofloxacin and t1 with all four ver-
sions of the enzyme (Supplementary Figure S4; wt, S83L,
D87A, D82N) and the results largely mirror our IC50 mea-
surement, i.e. for each compound the resistance profile ob-
tained from IC50 values being similar to the one obtained
from CC50 values.
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Figure 2. The 3.06 A˚ structure of t1 with Staphylococcus aureus DNA gyrase and DNA. (A) View down the 2-fold axis of the 3.06 A˚ structure of t1 with
S. aureusDNA gyrase and DNA (one of two such complexes in the asymmetric unit). Note the 20 bp DNA duplex has been cleaved by tyrosines 123 (and
123’). (B) Orthogonal view of the complex with the 2-fold axis vertical. (C) Detailed view showing the two compounds (t1 and t1’) bound at the two DNA
cleavage sites. (D) t1 binds in the DNA at the cleavage site, making interactions with S. aureusGyrA residues SaS84, SaR122 and the main-chain carbonyl
of GyrB Arg 458. (E) An equivalent view of the 2.95 A˚ moxifloxacin complex showing the water–metal–ion bridge.
Table 1. Supercoiling IC50 values for various mutants and compounds (in M)
wild-type EcS83L EcD87A EcD82N
ciprofloxacin 0.45 8.7 3.2 4.7
t1 0.5 3.7 0.5 9.4
t2 1.7 9.5 1.7 4–20*
t3 1.6 12.0 1.6 4–20*
b1 2.6 1.0 ND ND
b2 5.2 11.0 ND ND
All these values were obtained with single preparations of wild type and mutant E. coli DNA gyrase; the GyrB subunit preparation was the same across
all these measurements. Repeating these measurements with different preparations gave values that did not deviate by more than a factor 2. * The data
could not be fitted so an approximate value was determined visually, i.e. the lower concentration of the indicated range gives more than 50% supercoiling
and the higher concentration gives less. ND: Not Determined.
We have tested other compounds in the series for both
cleavage and supercoiling inhibition, including two bicyclic
IPYs (b2 and b1, Figure 1), which had been briefly consid-
ered as initial starting points for an optimization program
(Jeannot et al. In revision in J Med Chem). Like all the tri-
cyclic IPYs tested, they proved able to inhibit supercoiling
and stabilize cleavage by gyrase. The CC50 and IC50 values
gave a good correlation across both bicyclic and tricyclic
compounds (Tables 1 and 2) suggesting that the inhibition
of supercoiling stems from the stabilization of gyrase–DNA
cleavage complexes. The bicyclic IPY b1 surprisingly dis-
played improved activity toward the EcS83L mutant en-
zyme compared to the wt (Table 1). The difference is small
but was reproduced with two independent preparations of
both the mutant and wt enzyme. Interestingly the other bi-
cyclic IPY, b2, was less active against EcS83L, similar to the
tricyclic series. Compound b2 has a methyl group instead of
a phenyl group attached to the pyrazinone core, suggesting
that the small methyl group allows a binding mode simi-
lar to the tricyclic series, whereas encumbering it with the
bigger phenyl group may change the binding mode, thereby
altering the resistance profile.
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Figure 3. Inhibition of Escherichia coli DNA gyrase supercoiling by t1 (A) and ciprofloxacin (B). The extent of supercoiling is defined as the proportion
of supercoiled plasmid within the total material in the lane (supercoiling assay performed as described in ‘Materials and Methods’ section) and is plotted
against compound concentrations (in M). The diamonds are data points. The smooth curves are the best fit of a logistic function to the data points
(‘Materials and Methods’ section). Ciprofloxacin (B) encounters resistance from all three mutants tested compared to the wt (curves are shifted to the
right, see Table 1 for IC50 values). t1 encounters resistance from EcS83L and EcD82N but not EcD87A. The color-coded numbers next to the curves are
the IC50 values (also reported in Table 1).
Table 2. Cleavage CC50 values for various compounds on wild-type E.
coli DNA gyrase
Compound CC50 (M)
ciprofloxacin 0.18
t1 0.75
t2 2.25
t3 1.08
b1 4.45
All these values were obtainedwith a single preparation of wild-typeE. coli
DNAgyrase. The CC50 value is defined as the concentration giving half the
total amount of cleavage obtained at saturating amount of compound.
The cleaved state compared to an uncleaved binary enzyme–
DNA complex
To gain insight into the conformational transitions involved
in the formation of a ternary cleavage complex, we solved
the structure of a binary complex involving the same S. au-
reus gyrase core construct andDNA. Even though the over-
all conformation of this binary complex (Figure 4A and
B) is quite similar to the IPY-poisoned ternary complex,
this binary complex presents some clear differences from
the IPY complexes and all other S. aureus complexes with
DNA (19,29–30). In the IPY structures and all previously
published S. aureus complexes with DNA, the WHD and
TOPRIM domains within a subunit have been in approxi-
mately the same orientation ((29) and Supplementary Fig-
ure S5F). However, in the binary complex the TOPRIM
domain is rotated by ∼12◦ around the A1 hinge (this
hinge region is discussed elsewhere (21)), so that the metal-
coordinating residues on the TOPRIM domain, including
D508, have moved too far away from the DNA, prevent-
ing the metal ion from binding to the TOPRIM domain
and also contacting the DNA (Figure 4C–H). In the binary
complex, which is crystallized from the same crystallization
conditions as many other S. aureus complexes, no metal ion
is observed at the TOPRIM domain catalytic site.
Comparison of an IPY-poisoned ternary complex with
the binary complex (Figure 4C–H; Supplementary Figures
S5 and 6) shows a sliding motion of the two GyrA subunits
past one another when transitioning from the binary to the
ternary complex. The relative position of the two WHD
domains in the binary complex resembles that seen in the
apo S. aureus structure (PDB code: 2XCQ; (19)). In the bi-
nary complex the distance between the two scissile phos-
phates is 21.7 A˚, and the DNA in this central region is in an
A-DNA conformation (Supplementary Table S2). In con-
trast, in the 2.1 A˚ GSK299423 (an NBTI) structure with
uncleaved DNA (PDB code: 2XCS; (19)), the distance be-
tween the two scissile phosphates is 25.7 A˚, and metal ions
are observed contacting the scissile phosphate (Supplemen-
tary Figures S5 and 6; (19)).
The SaD83 residue (equivalent to EcD82) is situated at
the ‘sliding interface’ between the two GyrA subunits (Fig-
ure 4C–E). The two SaD83 residues move apart when the
complex transitions from the binary (unpoisoned) to the
ternary (poisoned) conformation. Therefore, we surmise
that mutation of this residue could influence the respective
energetics of those two states and may have a net stabi-
lizing effect on the binary complex. Modeling a SaD83N
mutation in the binary complex suggests that the unfavor-
able interaction between the two aspartic acid side-chains
(SaD83) observed in the binary complex can be replaced by
two hydrogen bonds (not shown). The EcD82N mutant is
predicted to stabilize the uncleaved DNA conformation ob-
served in the binary complex (and the apo structure) relative
to cleaved conformations such as those observed in the IPY
complexes (Figure 4).
The EcD82N mutation inhibits ATP-induced intrinsic DNA
cleavage
Our structures reveal a degree of similarity between the
binding mode of FQs and the tricyclic IPYs to DNA gy-
rase that is reflected by the cross-resistancewith S83L.How-
ever, mutation of EcD87, being involved in the binding of
FQs and not t1, only confers resistance to FQs such as
ciprofloxacin (Table 1). In contrast, the EcD82N mutation
confers resistance to both compounds, while not making
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Figure 4. Comparison of the binary 2.65 A˚ complex ofStaphylococcus aureusDNAgyrase andDNA,with the 3.11 A˚ t3 complex. (A andB) Two orthogonal
views of the 2.65 A˚ binary BA BA’ complex. The BA subunit is shown in cartoon representation, the BA’ subunit in ribbon, the DNA is shown in stick
representation. (C) Detailed view of the central region of the DNA in the binary complex, the central DNA is in A-DNA conformation. D508 from the
TOPRIM domain does not bind a metal ion, presumably because it is too far away from the DNA for the metal ion also to interact with the DNA (cartoon
and sticks are shown semi-transparent for clarity). Note that D83 and D83’ side-chains are in van der Waals contact at the twofold axis. (D) Equivalent
view of the central region of the 3.11 A˚ structure of t3 cleavage complex. (E) Superposition of D and E. (F and G) Schematics of domain orientations in
the binary complex and the t3 complex. (H) Superposition of F and G.
direct contact with IPYs or FQs (Figure 2; SaD83). We
hypothesized that the EcD82N mutation impairs the for-
mation of a gyrase–DNA cleavage complex for both com-
pounds by stabilizing the uncleaved conformation relative
to the cleaved conformation rather than influencing com-
pound binding per se.
It is known that adenosine triphosphate (ATP) is required
for multiple strand-passage events by gyrase. The catalytic
cycle involves a transient cleaved intermediate presumably
resembling the permanent cleavage complex stabilized by
compounds. We tested the ability of ATP to induce cleav-
age on the wt, EcS83L, EcD82N and EcD87A versions of
theE. coli enzyme in the absence of any compounds (Figure
5). As expected, omission of ATP brings the cleavage level
to nearly zero for all enzymes at any Mg2+ concentration
(not shown). Likewise, in the absence ofMg2+ no cleavage is
observed for all four enzymes, whereas increasing amounts
of Mg2+ in the presence of ATP allows the detection of in-
creasing amounts of DNA cleavage for all the mutants ex-
cept with the EcD82N enzyme, which fails to cleave DNA
significantly in the presence of Mg2+ (Figure 5). We have
been able to stabilize equivalent levels of cleavage between
the D82N preparation and the other versions of the enzyme
at saturating ciprofloxacin concentration (500 M, Supple-
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Figure 5. The D82N mutation affects the natural ability of DNA gyrase
to cleave DNA with Mg2+ and ATP as co-factors. (A) Cleavage assays
performed in the absence of compounds with wt, EcS83L, EcD82N and
EcD87A versions of the enzyme in the presence of ATP and either 0, 4,
8 or 15 mM MgCl2 added to the reaction. A no enzyme control (no enz)
was also performed in the same conditions to assess the baseline of the
assay. Mg2+ induces cleavage with all enzyme versions except EcD82N.
This cleavage is also dependent on ATP (not shown) for all versions of the
enzyme. The slight migration shift of the intact band is due to the intro-
duction of negative supercoiling which for all mutants and wt is dependent
on ATP andMg2+ (it is not observed in the no enzyme control). (B) Quan-
titation of the experiment in A. The average proportion of linear plasmid
from three repeats for each point is plotted against MgCl2 concentration.
The error bars are the standard deviation for the three repeats. For each
enzyme versions, the amount of enzyme used was normalized at 2 g per
assay. This amount is higher used in Figure 1 (250 ng), 6 and 7 (400 ng)
as cleavage is much lower in the absence of compound and therefore more
enzyme is necessary to achieve detectable cleavage.
mentary Figure S4). This shows that the D82N enzyme is
still competent in utilizing Mg2+ to cleave DNA although
it is much less efficient in stabilizing the cleaved state. This
control rules out a higher incidence of inactive enzyme (i.e.
misfolded) in the D82N preparation.
Ciprofloxacin- and t1-induced cleavage complexes have a dif-
ferent Mg2+ dependency and similar kinetics of appearance
The absence of the water–metal–ion bridge in the IPY struc-
tures prompted us to investigate the IPY cleavage com-
plex’s sensitivity to the presence of Mg2+. We compared
the kinetics of resealing in the presence of EDTA for both
ciprofloxacin and t1 (Figure 6B and C). We found that
EDTA efficiently reseals ciprofloxacin-stabilized cleavage;
the resealing occurred with a single-stranded cleaved inter-
mediate (nicked). This nicked form appeared very quickly
(within 15–30 s depending on the compound) in the reseal-
ing kinetics experiment, concomitant with the disappear-
ance of linear DNA; conversely its disappearance was slow.
The kinetics of resealing of cleavage stabilized by t1was very
similar although the disappearance of the linear double-
strand cleavage was slower, as was the appearance of the
intact re-ligated form (Figure 6B and C). Consistent with
this, the kinetics of appearance and disappearance of the
nicked formwas also slower with t1 thanwith ciprofloxacin.
The simplest explanation for these observations is that re-
sealing occurs sequentially between the two cleavage sites.
Re-ligation of one strand makes the linear form disappear
and concomitantly produces the nicked form. The final re-
sealing event might be slower or potentially affected by the
EDTA treatment (see Discussion). Slower resealing of t1-
induced cleavage by EDTA is consistent with the lack of a
water–metal–ion bridge stabilizing the complex as opposed
to the FQs.
It is interesting to see EDTA efficiently reversing the t1-
stabilized cleavage, albeit at a reduced rate, despite the ab-
sence of a water-metal ion bridge. This suggests that the
primary effect of EDTA during t1-induced cleavage rever-
sion is to strip themetal ions from the catalytic cleavage site,
thereby inducing resealing (whereas EDTA treatment pre-
sumably also destabilizes the water-metal bridge of the FQ
ternary complex, thereby explaining the faster re-sealing ki-
netics). This would suggest that the catalytic-core metal is
essential for cleavage maintenance.
Replacing Mg2+ by Ca2+ in the reaction has been shown
to stabilize double-stranded DNA-cleavage by gyrase (24).
However, unlike poisoning by the FQs, the enzyme is still
able to introduce negative supercoils (which we confirmed
in our experiments; not shown). Since Ca2+ ions can be
chelated by EDTA (40), we performed the same experiment
as above (Figure 6D) but with Ca2+ in place of Mg2+. The
kinetics of resealing of Ca2+-induced cleavage is slower but
strikingly similar to the profile displayed by FQs and IPYs.
The disappearance of the linearDNA closely coincides with
the appearance of the nicked DNA.We have independently
fitted both datasets to single exponentials and the rate of
linear disappearance was found to be very close to the rate
of nicked appearance (0.11 and 0.12 min−1, respectively).
Unlike the FQs and IPYs the amount of uncleaved DNA
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Figure 6. Sensitivity to EDTAof cleavage complexes stabilized by the IPYs, ciprofloxacin andCa2+. (A) Outline of the experiment. The initial 15min allows
for the formation of cleavage complexes, which are then reversed by the addition of 8 mM EDTA (final). The SDS trapping is performed at various times
after EDTA addition as for a normal cleavage assay (‘Materials andMethods’ section). One sample is kept free of enzyme for each of the three experiments
and is trapped after the first 15 min. All three experiments are performed in the absence of ATP. (B) Reversion of ciprofloxacin cleavage complexes. An
average of three repeats is plotted against the time spent in the presence of EDTA. The extent of cleavage is the proportion of each species to the total
of the lane. Error bars are the standard deviation as in Figure 5. (C) Reversion of t1 cleavage complexes, as in A and B. (D) Reversion of Ca2+-induced
cleavage complexes as in A and B, but note that the time frame is much longer in this case. Approximately 400 ng of A2B2 Escherichia coli wt gyrase was
used in each assay.
does not increase, showing that complete resealing does not
occur.
The single-strand cleaved form that we detected in the
re-sealing experiments is reminiscent of the single-strand
cleaved intermediate detected in the kinetics of appearance
of ciprofloxacin-induced cleavage (41). In that study, ATP
was shown to stimulate strand passage through the DNA
gate by DNA gyrase. This result therefore suggests that
the opening of the DNA gate greatly accelerates the for-
mation of the cleavage complex. This is presumably due to
ciprofloxacin not being able to directly trigger cleavage, but
only to stabilize a cleaved conformation that is formedmore
readily whenATPhydrolysis is available to facilitate the par-
tial opening of the DNA gate. To test whether the IPYs
would behave similarly in terms of the kinetics of cleavage,
we performed a cleavage assay in which the cleavage was
initiated by adding the enzyme to a mixture of DNA sub-
strate and the relevant compound (ciprofloxacin or t1) in the
usual reaction buffer and transferred at 25◦C. The cleavage
was then trapped by SDS at various times. The reactions
were carried out either in the presence or absence of ATP
for both compounds. We found that in both cases the pres-
ence of ATP greatly stimulated the rate of appearance of
the linear DNA (Figure 7). Moreover, the linear DNA ap-
peared at a similar rate for ciprofloxacin and t1. We have
quantified the product for the reaction carried out in the
absence of ATP and found a similar rate for the appearance
of linear DNA. In addition, a detectable nicked intermedi-
ate was observed for both compounds, again with similar
rates (Figure 7). Our results are in line with previous results
obtained for ciprofloxacin (41). This is consistent with an
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Figure 7. Kinetics of cleavage for ciprofloxacin and t1. The top panels show the results of cleavage assays with various times allowed for the formation of
the cleavage complexes as indicated. The experiment was performed in the presence and the absence of ATP as indicated. The plot shows the quantitation
for the minus ATP conditions only. The extent of cleavage is determined as in Figure 5. The data were fitted with a simple two-step process; it is indicative
only. The single-strand intermediate and ATP stimulation of the kinetics of cleavage are apparent for both compounds. The rate of appearance is also quite
similar for both compounds. Approximately 400 ng of A2B2 Escherichia coli wt gyrase was used in each assay.
analogous binding and poisoning mechanism for the IPYs
compared to the FQs.
DISCUSSION
The IPYs poison DNA gyrase by binding the quinolone
pocket in a similar orientation to the one adopted by FQs
In this study, we have characterized a new class of non-
quinolone bacterial topoisomerase inhibitors, the IPYs, and
show that they efficiently inhibit the supercoiling activity
of purified DNA gyrase due to their ability to stabilize a
cleavage complex. This underlies their antibacterial activ-
ity as the cross resistance we observed in vitro is mirrored
in whole cells with bacterial strains bearing FQ-resistance
mutations in the gyrase genes (Jeannot et al. In revision in
J Med Chem). Overall, we observed some correlation be-
tween the CC50/IC50 of compounds and their whole cell an-
tibacterial activity. Taken together, this is consistent with a
bactericidal action stemming from the stabilization of cleav-
age complexes, similar to the FQs. The orientation adopted
by the tricyclic IPY t1 was also similar to that adopted by
FQs despite lacking the keto-carboxylic moiety that allows
the FQ to directly contact DNA gyrase through a water-
Mg2+ ion bridge. This is reminiscent of the binding mode
of the quinazolinediones (42). Many structurally unrelated
compounds are able to intercalate in the same position sug-
gesting some flexibility in the ligand-binding pocket. This
is consistent with a previous report suggesting two modes
of binding for the FQs (43). Moreover, the DNA gate is a
dynamic part of the molecule, being able to open to allow
a DNA segment pass through, which might contribute to
the flexibility in accommodating compounds. However, the
IPYs are likely to establish some interactions with the DNA
and/or protein that mirror those established by the FQs, al-
lowing them to adopt a similar orientation. These interac-
tions could be van der Waal forces and/or stacking inter-
actions in addition to a direct interaction with the SaS84
residue.
The structures of the tricyclic IPYs bound to the S. au-
reus core gyrase were supported by measuring the ability of
the compounds to inhibit negative supercoiling by gyrase
and key mutant forms of the enzyme. The tricyclic IPYs
contact, via a hydrogen bond, S. aureus S84 (equivalent to
EcS83) but do not contact SaD88 (EcD87) whereas the FQs
establish a water–metal–ion bridge involving both residues
(Figure 2D and E). Our experiments consistently showed
that the EcS83L and EcD87A mutations both rendered gy-
rase resistant to inhibition by ciprofloxacin whereas the IPY
compounds encountered resistance from EcS83L but not
EcD87A. This was true for all three tricyclic IPYs tested.
The case of the EcD82 residue is more complex. It does not
contact either the FQs or the IPYs but its mutation to an
asparagine confers resistance to both at a high level. In con-
trast to EcS83 and EcD87 whose activity can be explained
by their direct interaction with compounds, the D82N mu-
tation seems to work by a different, ‘allosteric’ mechanism.
The D82N mutation stabilizes uncleaved DNA suggesting a
thermodynamic model for poisoning
The foregoing results suggest a distinction between residues
whose mutation confers resistance to poisoning com-
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pounds. One class of residue (e.g. EcS83 and EcD87) would
simply be involved in the binding and/or proper orienta-
tion of the compounds for poisoning: ‘direct’ mutations.
The other class (e.g. EcD82) would be generally involved in
stabilizing the poisoned conformation or destabilizing the
uncleaved conformation: ‘allosteric’ mutations. Our data
show that, not only does the D82N mutant show resis-
tance to IPYs and FQs (Figure 3 and Table 1), this mu-
tation also inhibits the ATP-induced stabilization of both
single- and double-cleaved DNA (Figure 5). In the 2.6 A˚
binary structure with uncleaved DNA, the equivalent S. au-
reus residue, D83, makes direct contact with its counterpart
across the 2-fold axis (Figure 4). The mutation of the neg-
atively charged aspartic acid side-chain (EcD82/SaD83) to
an asparagine allows two hydrogen bonds to be made be-
tween the side-chains of Asn83, which we suggest will sta-
bilize the binary complex with uncleaved DNA compared
to the cleaved complex. If true, this would suggest that mu-
tating this residue to an alanine, which is not able to form a
similar hydrogen bond, would confer a lower level of resis-
tance. This is indeed suggested by data reported previously
(44), considering the low level of resistance of D82Amutant
compared to the S83L mutant in MIC assay.
In the binary crystal structure (Figure 4) the central 4 bp
of DNA between the two active sites are in an A-DNA-like
conformation and the distance between the scissile phos-
phates is 21.7 A˚ (Supplementary Figure S7). In contrast,
two previous crystal structures of bacterial type IIA topoi-
somerase with uncleaved DNA showed the central 4 bp of
DNA stretched between the two catalytic sites so that the
distance between the two scissile phosphates is 25.7 or 25.5
A˚ (Supplementary Figure S7) (19,42). It is presumably not
thermodynamically favorable for the DNA gate to adopt
this partially opened conformation as it extends the DNA
into a non-A conformation and reduces the extent of in-
teraction at the protein interface (Figure 4). Therefore, for
a compound to successfully intercalate and poison the en-
zyme, the binding energy afforded through direct contact
would have to compensate for the unfavorable opening of
the DNA gate. Within that view, any factor that influences
the intrinsic dynamics of the DNA gate (i.e. the free en-
ergy of this transition between closed and partially opened)
would also influence its ability to be poisoned (Figure 8).
The partial opening of the DNA gate is achieved by a con-
formational change involving a tilting of the TOPRIM do-
main and is likely coupled to divalent metal capture, which
allows DNA cleavage. Consistent with this hypothesis, our
binary complex structure does not involve any metal at the
catalytic cleavage sites.
The intercalation of compounds and partial opening of
theDNAgate is also coupled with a sliding of the twoGyrA
subunits relative to one another. (Structural transitions in-
volving sliding of interfaces in type II topoisomerases has
also been suggested in work on human topoisomerase II
(45,46).) Within the binary complex of the S. aureus gy-
rase core, the EcD82 residue from each side of the dimer
point toward each other at the dyad axis. The EcD82Nmu-
tation reduces the ability of the enzyme to cleave DNA in
the presence of ATP, without any compound present. This
suggests that the EcD82N mutation disfavors the cleaved
state even when no intercalating compound is present. We
surmise that the structural change observed between the bi-
nary and ternary complexes resembles the one that the en-
zyme undergoes during its normal strand-passage activity,
stimulated by ATP. Interestingly, the GyrA sliding interface
constitutes the binding pocket of the novel bacterial type
II topoisomerase inhibitors (NBTIs) (19), again consistent
with this sliding motion being involved in transition to the
cleaved state. Moreover, mutation of the EcD82 residue in
E. coli and the equivalent residue in Pseudomonas aerugi-
nosa can confer resistance to the NBTIs (47). This could be
due to the direct interaction of the residue with the NBTI;
however it is tempting to speculate that EcD82’s intrinsic
function in cleavage also plays a role.
Other residues whose mutation confers resistance have
been characterized that do not contact the poisoning com-
pound in any obvious manner. For instance, in work by Al-
dred et al. (48), a Bacillus anthracis topo IV mutant confers
resistance to both FQs and quinazolinediones and is likely
not involved in directly contacting either. We surmise that
this is a case analogous to the EcD82N mutation. More-
over a Schizosaccharomyces pombe topo II mutant has been
shown to display intrinsically higher DNA cleavage activ-
ity in the presence of ATP (and absence of compound) (49)
and confers upon yeast cells hypersensitivity to doxorubicin
(50) and TOP-53 (an etoposide derivative; Germe, T. and
Cooper, J.P., unpublished data), both of which are able to
poison topo II by intercalation at the cleavage site, much
like the FQs. Although a direct interaction of both struc-
turally unrelated compounds with this residue in yeast topo
II cannot be ruled out (however unlikely), this suggests a
mirror case of EcD82N and furthermore suggests that mu-
tations that affect the intrinsic ability to cleave DNA also
affect poisoning in all type IIA topoisomerases.
Presumably, ATP hydrolysis favors the structural tran-
sition that we call ‘partial opening’ as a pre-requisite for
strand passage. This is consistent with the observation that
ATP favors Mg2+-dependent cleavage by the unpoisoned
enzyme (Figure 5).We have also shown thatATP accelerates
the poisoning of gyrase by both ciprofloxacin and t1 (Fig-
ure 7), which is consistent with the dynamics of the enzyme
being intrinsically involved in the efficiency of poisoning.
The kinetics of appearance of cleavage complexes were
strikingly similar between ciprofloxacin and t1, occurring at
a comparable rate and with a detectable single-strand bro-
ken intermediate, as reported previously for ciprofloxacin
(41). This work also suggested that ciprofloxacin binding
occurred quickly, indeed faster than the rate of cleavage ap-
pearance, and it was also reported that cleavage is not nec-
essary for the binding of ciprofloxacin to the enzyme–DNA
complex (51). It is therefore likely that the kinetics of cleav-
age reflect the rate at which the enzyme can reach the cleaved
state rather than the rate of binding of the compound. We
hypothesize that the IPY series also binds quickly to the
enzyme, the similar kinetics reflecting a similar path to the
cleaved state, through a single-strand broken intermediate.
The role of the metal at the cleavage site
We compared the EDTA-induced re-sealing dynamics of
the cleavage complexes stabilized by either ciprofloxacin
or t1. The addition of EDTA results in the re-sealing of
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Figure 8. Thermodynamic model for the poisoning of DNA gyrase. Two factors that contribute to the free energy of poisoning can be distinguished. First,
the conformational transition from an uncleaved complex to a cleaved complex, coupled with the sliding of the GyrA subunit, the tilting of the TOPRIM
domain and the stretching of theDNAat theDNAgate. This favorsmetal-ion capture and therefore cleavage. This transition is presumably not energetically
favorable and constitutes a ‘prelude’ to the full opening of the DNA gate for strand passage. Second, the binding of the compound to this general poisoned
conformation which stabilizes it through its favorable binding energy. EDTA addition strips the metal from the poisoned conformation, which results in
re-sealing. In the case of ciprofloxacin it presumably also destabilizes the ternary complex, resulting in a transition toward the binary complex and the
catalytic Mg2+ being expelled at a higher rate. This is consistent with our observation of a higher re-sealing rate by EDTA for the ciprofloxacin cleavage
complexes as compared with t1.
double-stranded cleavage complexes stabilized by t1 as well
as those stabilized by ciprofloxacin (Figure 6). Since no
water-Mg2+ bridge is involved in the binding of t1, the ef-
fect of EDTA is most likely to remove the Mg2+ from the
cleavage site, destabilizing the cleavage competent confor-
mations of the enzyme (Figure 8). Our data suggest that
Mg2+ is essential for the maintenance of the cleaved state
for both compounds (Figure 6). In addition, the faster re-
sealing kinetics for ciprofloxacin is consistent with the hy-
pothesis that re-sealing could occur both by stripping the
compound from the enzyme (through the destabilization of
the water–metal–ion bridge) and also by stripping the metal
from the catalytic sites. In the case of t1, since no metal is
involved in binding, the compound would presumably re-
main bound to the enzyme, unaffected by EDTA, re-sealing
occurring only through stripping of the metal from the cat-
alytic sites and therefore with slower kinetics. The tricyclic
IPYs are therefore reminiscent of the quinazolinediones,
which also show a reduced sensitivity for Mg2+ due to the
absence of a water–metal–ion bridge and, like the IPYs, by-
pass some FQ-resistance mutations (39,52–53).
The re-ligation also involves a single-strand intermediate
for both t1 and ciprofloxacin (Figure 6). This nicking is not
observed with the enzyme alone at this concentration and
it is transient, although slow to disappear completely. The
ability of gyrase to stabilize single-stranded cleavage com-
plexes has been observed before with the thiophene com-
pounds and NBTIs (19,21). It has also been observed that
ATP induces a detectable single-stranded cleavage complex
with the unpoisoned enzyme (i.e. without compounds) (21).
The single-strand cleaved state, which constitutes an in-
termediate during re-ligation, is stabilized by both t1 and
ciprofloxacin. Interestingly when we investigated re-ligation
of cleavage induced by Ca2+ we observed similar results
(Figure 6D). It should be noted that Ca2+ can sustain nega-
tive supercoiling, albeit at a reduced rate (our unpublished
data). Addition of EDTA to remove the Ca2+ also results in
resealing on one side, converting double-cleaved to singly-
cleaved DNA (Figure 6D). However, unlike ciprofloxacin
and t1, the single-strand cleavage observed after EDTA
treatment of Ca2+-stabilized cleavage complexes persists.
This suggests an asymmetry between the twometal-binding
catalytic sites, and that the first and secondDNA-re-ligation
steps are different, at least in the presence of calcium.
Nicking induced by EDTA has been observed by other
investigators (52,53). However, it remains unclear how this
nicking arises. We observed that EDTA also fails to re-seal
the nicking observed with the unpoisoned enzyme in the
presence ofATP (data not shown and (21)).We propose that
the enzyme can naturally reach a single-strand cleaved state
after which resealing can be affected by EDTA. Moreover,
we believe this state is an obligatory intermediate during re-
ligation.
It has been proposed that type IIA topoisomerases cat-
alyze cleavage through a two-metal mechanismwith two co-
ordination sites formetal ions (normallyMg2+ although it is
replaced by Mn2+ in the S. aureus gyrase crystal structures)
(54–57). The A-site coordinates a metal ion that can di-
rectly catalyze the transesterification reaction, whereas the
B-site contacts the next, non-scissile phosphate via a wa-
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ter molecule (Supplementary Figure S6) and is thought to
have a ‘DNA-docking’ function for cleavage. Across the ar-
ray of gyrase core structures in which the DNA is cleaved by
the enzyme, a metal has generally been observed at the B-
site (3′). Only with an uncleaved ternary complex (with the
NBTIs) has the metal been observed at the A-site (where
it presumably directly catalyses cleavage and/or re-ligation)
(19). It should be noted that cleavage and re-ligation do
not necessarily occur identically. For instance, the ‘dock-
ing’ function of the B-site is presumably superfluous for
re-ligation, when the DNA is already cleaved and held in
proximity by the phospho-tyrosine bond. At the A-site, the
metal contacts the scissile phosphate (unlike the B-site) and
it therefore is reasonable that this coordination site would
change upon cleavage and DNA gate opening, resulting in
the metal leaving the A-site but not the B-site, explaining
the lack of metal in the A-site only in structures of gy-
rase bound to already cleaved DNA. Therefore, re-ligation
would would need to recruit metal ion from the solution
or, we speculate, the B-site, since the docking function is no
longer required after cleavage.
The observation that EDTA treatment results in resealing
on one side only suggests that stripping the metal from one
site results in resealing, whereas themetal from the other site
is not stripped at the same rate. If the propensity of themetal
to be pulled from the B-site to the A-site is affected by the
structural asymmetry of the cleavage complex, one could
imagine that on the side where this motion is hindered, the
metal could be stripped without going through the A-site,
thereby producing an ‘un-re-sealable’ single-stranded cleav-
age complex, consistent with our observations. If the mo-
tion is unhindered, the metal is readily able to go through
the A-site before being stripped and therefore the net re-
sult would be resealing. This is consistent with the observa-
tion that higher EDTAconcentrations produce higher levels
of nicking (52). A high concentration of EDTA would fa-
vor stripping the metal from the B-site before it had time
to move back to the A-site, thereby producing an un-re-
sealable complex with no metal complexed to cleavage site.
This metal motionwould therefore be coupled to the con-
formational transition to a binary complex (namely the tilt-
ing of the TOPRIM domain away from the cleavage site
on DNA). This is consistent with our observation of a bi-
nary complex devoid of metal at the cleavage site. It is also
consistent with the observation of fast re-sealing kinetics
of ciprofloxacin–gyrase–DNA cleavage complexes. EDTA-
mediated destabilization of the ternary complex (due to
destabilization of the water–metal–ion bridge) favors tran-
sition to the binary complex, which in turn favors the metal
ion moving to the A-site, catalyzing re-ligation and leaving
the enzyme. We further speculate that the transition to the
binary complex state occurs sequentially (one side of the
dyad axis after the other) thereby explaining our observa-
tion of a single-strand intermediate.
Asymmetry between the two sides has been observedwith
structures of etoposide gyrase–DNA cleavage complexes
(29). Etoposide stabilizes a mixture of single- and double-
strand breaks and we observed that this single-strand cleav-
age cannot be re-sealed by EDTA, correlating a structural
asymmetry of the cleavage complex with an asymmetry
in EDTA sensitivity (unpublished data). This is consistent
with the relative motion of the TOPRIM domains and
WHD domains, which control DNA extension, also con-
trol the status of the metal at the cleavage site.
A possible alternative orientation for the binding of bicyclic
IPY in the same pocket
The tricyclic IPY compounds adopt an orientation that still
favors contact with EcS83 and results in cross-resistance
with quinolones. One bicyclic IPY (b1) did not display
cross-resistance with the S83L mutant but rather showed
an increased activity against that mutant; the S83L mutant
was resistant to the other bicyclic tested, much like the tri-
cyclic compounds. The differences between the two bicyclic
IPYs are a chlorine substituent on the top aromatic ring for
b2 that is not present for b1 (Figure 1) and the pyrazinone
core is substituted on N1 by a methyl for b2 and by a much
bulkier phenol group for b1. It is the protruding imidazo
nitrogen atom of the IPY moiety that establishes contact
with S83 in the case of the tricyclic compounds. The simpler
interpretation is therefore that the same atom establishes
contact with S83 in the case of b2 explaining the resistance
data. Compound b1 would itself adopt a different confor-
mation within the pocket that is favored by the absence of
S83. One possibility could be that the phenolic group on b1
prevents the IPY from establishing contact with S83, forc-
ing the compound to adopt a different orientation. It would
be interesting to determine this putative alternative orien-
tation as it could open new avenues for the development of
new poisons. Although the bicyclic IPYs present a possible
avenue to develop new intercalative poisons for antibiotic
purposes, their low activity against the enzyme and lack of
significant antibacterial activity would have to be overcome
and there is currently no obvious route for this optimiza-
tion.
Summary and general conclusion
In conclusion, the IPYs have been shown to bind to the
FQ pocket of gyrase in a fashion similar to the FQs de-
spite the exchange of the 4-oxo and carboxylic acid groups
of FQs for a fused imidazole moiety in IPYs. These IPYs
were shown to have partial cross-resistance with the FQs
which led to the termination of their optimization. This
study also points toward a general poisoning mechanism
whereby the partial opening of the DNA gate, involving lat-
eral sliding of the two GyrA subunits against each other
and tilting of the TOPRIM domains toward the dyad axis,
favors Mg2+ capture and DNA cleavage. Compounds poi-
son the enzyme by impeding the closure of the DNA gate,
their binding/intercalation energy compensating for the en-
ergetic cost of keeping the DNA stretched, and the DNA
gate partially opened, thus favoring a conformation where
DNA can readily be cleaved, catalyzed byMg2+. This open-
ing of theDNAgate could involve some asymmetry causing
the two cleavage sites to not be competent for re-ligation at
the same time. Our data suggest a model in which this is due
to differing ability in mobilizing the metal from the B-site
(where it is seen in crystal structures) to the A-site (where
it catalyses the re-sealing reaction), although this is only a
speculative model and our data do not contradict the two-
metal model proposed for cleavage. In addition, our results
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with the bicyclic IPYs also suggest a degree of flexibility in
the orientation of compounds within the binding pocket,
which could have implications for medicinal chemistry ef-
forts in the development of new bacterial topoisomerase II
poisons that are able to circumvent target-mediated resis-
tance to FQ.
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